Sphera Funds Management’s Mineralys Therapeutics MLYS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$33.2M Sell
1,321,861
-148,110
-10% -$4.03M 4.7% 1
2026
Q2
$39.7M Buy
1,469,971
+130,000
+10% +$3.57M 5.17% 2
2026
Q1
$36.3M Buy
1,339,971
+890,968
+198% +$26.1M 5.76% 1
2025
Q4
$16.3M Buy
449,003
+229,093
+104% +$9.19M 3.15% 3
2025
Q3
$8.34M Sell
219,910
-261,064
-54% -$5.65M 1.76% 13
2025
Q2
$6.51M Buy
480,974
+15,448
+3% +$224K 1.53% 18
2025
Q1
$7.39M Buy
465,526
+274,854
+144% +$3.16M 1.7% 15
2024
Q4
$2.35M Sell
190,672
-81,800
-30% -$1.07M 0.42% 76
2024
Q3
$3.3M Sell
272,472
-170,280
-38% -$2.06M 0.53% 56
2024
Q2
$5.18M Sell
442,752
-216,051
-33% -$2.72M 0.71% 48
2024
Q1
$8.51M Sell
658,803
-84,788
-11% -$1.05M 1.2% 30
2023
Q4
$6.39M Buy
743,591
+288,191
+63% +$2.26M 1.03% 38
2023
Q3
$4.33M Buy
455,400
+50,000
+12% +$652K 0.79% 46
2023
Q2
$6.91M Buy
405,400
+66,400
+20% +$992K 1.08% 31
2023
Q1
$5.31M Buy
+339,000
New +$5.71M 0.89% 41

Other funds holding MLYS

Sphera Funds Management's MLYS Position: Q3 2026 in Review

Sphera Funds Management reduced its Mineralys Therapeutics (MLYS) stake by 10% in Q3 2026, selling an estimated $4.03M and leaving 1,321,861 shares worth $33.2M. The position accounts for 4.7% of the portfolio, ranked #1.

Sphera Funds Management first reported a position in MLYS in Q1 2023 and has held it in 15 quarters since. The position peaked at $39.7M in Q2 2026. 218 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.

  • Sphera Funds Management held 1,321,861 shares of Mineralys Therapeutics worth $33.2M as of Q3 2026.
  • Sphera Funds Management sold 148,110 Mineralys Therapeutics shares in Q3 2026, an estimated $4.03M.
  • Mineralys Therapeutics made up 4.7% of Sphera Funds Management's portfolio in Q3 2026, its #1 holding.
  • Sphera Funds Management first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 15 quarters since.
  • Sphera Funds Management's Mineralys Therapeutics position peaked at $39.7M in Q2 2026.
  • 218 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.

Based on Sphera Funds Management's 13F filing for Q3 2026, filed 16 Nov 2026.